A unit dose pharmaceutical composition comprising 2.0 to 8.0 mg of a dry powder of one or more glucocorticoid or mineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof; wherein the composition is comprised in a syringe is disclosed. The composition may also comprise a a sterile, liquid carrier suitable for direct injection into an eye and/or 0.6 to 0.75% (w/v) of carboxy methyl cellulose (CMC); and 0.015 to 0.04 (w/v) of a surfactant. Also disclosed is a medical device comprising the unit dose pharmaceutical composition, use of the pharmaceutical composition in the treatment of an eye disease or condition or predisposition thereto and a method of treatment of an eye disease or condition or a predisposition thereto in a subject in need thereof including injecting into the eye the pharmaceutical formulation. The injection may comprise an intravitreal and/or suprachoroidal injection.

A unit dose pharmaceutical composition comprising 2.0 to 8.0 mg of a dry powder of one or more glucocorticoid or mineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof; wherein the composition is comprised in a syringe is disclosed. The composition may also comprise a a sterile, liquid carrier suitable for direct injection into an eye and/or 0.6 to 0.75% (w/v) of carboxy methyl cellulose (CMC); and 0.015 to 0.04 (w/v) of a surfactant. Also disclosed is a medical device comprising the unit dose pharmaceutical composition, use of the pharmaceutical composition in the treatment of an eye disease or condition or predisposition thereto and a method of treatment of an eye disease or condition or a predisposition thereto in a subject in need thereof including injecting into the eye the pharmaceutical formulation. The injection may comprise an intravitreal and/or suprachoroidal injection.

Disclosed are compositions and methods for treating or ameliorating the symptoms of cancer (e.g., oral cancer) by using a poly-pharmaceutical drug, whose composition consists of relationally optimized ratios of bioactive compounds to enhance their pharmacological characteristics.

Disclosed are compositions and methods for treating or ameliorating the symptoms of cancer (e.g., oral cancer) by using a poly-pharmaceutical drug, whose composition consists of relationally optimized ratios of bioactive compounds to enhance their pharmacological characteristics.

Provided herein is a pharmaceutical composition for treating cancers. The pharmaceutical composition includes an oil-in-water (o/w) microemulsion, and an active pharmaceutical ingredient dissolved therein. The o/w microemulsion is comprised of an aqueous solution, an oil, and a surfactant, and is about 5-250 nm in diameter. Also provided herein are methods for treating cancers by use of the present pharmaceutical composition.

Provided herein is a pharmaceutical composition for treating cancers. The pharmaceutical composition includes an oil-in-water (o/w) microemulsion, and an active pharmaceutical ingredient dissolved therein. The o/w microemulsion is comprised of an aqueous solution, an oil, and a surfactant, and is about 5-250 nm in diameter. Also provided herein are methods for treating cancers by use of the present pharmaceutical composition.

The present invention provides compositions for delivering cannabinoids to the nasal cavity. The subject invention utilizes a composition comprising one or more cannabinoids and an adjuvant mixture to enhance the delivery of the cannabinoid, benefitting the subject to whom the cannabinoid is delivered.

The present invention provides compositions for delivering cannabinoids to the nasal cavity. The subject invention utilizes a composition comprising one or more cannabinoids and an adjuvant mixture to enhance the delivery of the cannabinoid, benefitting the subject to whom the cannabinoid is delivered.

An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.

An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.